rs5985 — F13A1 Val34Leu

Factor XIII Val34Leu — The Clot Dissolubility Variant

Every blood clot is a scaffold of cross-linked fibrin, and the enzyme that builds that scaffold is Factor XIII-A (F13A1)¹¹ Factor XIII-A (F13A1)
a plasma transglutaminase activated by thrombin that cross-links fibrin chains, locks in alpha-2-plasmin inhibitor, and makes clots mechanically resistant to dissolution. The Val34Leu variant sits just three amino acids upstream of Factor XIII's thrombin cleavage site — close enough that the single valine-to-leucine swap fundamentally changes how fast the enzyme activates and what kind of clot it builds. Carriers of the Leu34 allele produce fibrin clots that are finer, more porous, and more accessible to fibrinolytic enzymes. The net result is moderate protection against venous thromboembolism and myocardial infarction, particularly in the setting of elevated fibrinogen.

The Mechanism

Factor XIII circulates in plasma as an inactive tetramer (two catalytic A subunits + two carrier B subunits). Thrombin cleaves the activation peptide from each A subunit, exposing the catalytic core. The Val34Leu polymorphism lies at position 34 of the A subunit — only three residues from the thrombin cleavage site at Arg37²² thrombin cleavage site at Arg37
thrombin cuts between Arg37 and Gly38 to activate Factor XIII.

This proximity is decisive. Biochemical studies show that Leu34 allele carriers have a significantly higher maximum rate of FXIII activation by thrombin³³ higher maximum rate of FXIII activation by thrombin
Wartiovaara et al., Thromb Haemost 2000 — the enzyme switches on faster after thrombin arrives. Earlier activation reshapes the fibrin architecture: FXIII that is active sooner cross-links fibrin before the growing polymer has fully polymerized, producing thinner fibers and a more open, permeable mesh. This porous clot structure is more accessible to plasmin, the fibrin-dissolving enzyme, making Leu34 clots easier to lyse.

A 2020 whole-blood clot study (86 donors)⁴⁴ 2020 whole-blood clot study (86 donors)
Kattula et al., J Thromb Haemost 2020 directly demonstrated that this effect is fibrinogen-concentration dependent: when fibrinogen is elevated, Val34 clots grow denser, but Leu34 homozygous clots do not show the same density increase. Since elevated fibrinogen is itself a thrombotic risk factor, the Leu34 allele specifically neutralizes one mechanism by which high fibrinogen promotes clotting.

The Evidence

The strongest evidence for protection against venous thromboembolism (VTE) comes from a meta-analysis of 12 studies (3,165 VTE cases, 4,909 controls)⁵⁵ meta-analysis of 12 studies (3,165 VTE cases, 4,909 controls)
Wells et al., Am J Epidemiol 2006. Leu34 homozygotes had an odds ratio of 0.63 (95% CI 0.46–0.86) for VTE — a 37% reduction in odds. Heterozygotes showed a smaller but still statistically significant protective effect (OR 0.89, 95% CI 0.80–0.99). The authors concluded that Val34Leu has a "small but significant" protective effect, though not large enough on its own to warrant clinical genotyping for VTE risk stratification.

The Leiden Thrombophilia Study⁶⁶ Leiden Thrombophilia Study
Van Hylckama Vlieg et al., Br J Haematol 2002 found that the protective effect in heterozygotes was modest (OR 0.9) but that Leu34 carriers had substantially elevated FXIII activity (158 vs. 95 units in Val/Val carriers), and protection was largely restricted to men.

For arterial disease, a Turkish case-control study found the Leu allele frequency was 7.69% in early MI patients vs. 19.23% in controls (p=0.0001)⁷⁷ Leu allele frequency was 7.69% in early MI patients vs. 19.23% in controls (p=0.0001)
Hancer et al., Circ J 2006, with the protective effect even stronger in patients under 50. A pharmacogenomics study by Undas et al. in Circulation 2003⁸⁸ Undas et al. in Circulation 2003 showed that low-dose aspirin (75 mg/day) selectively amplified FXIII activation rate in Leu34 carriers — raising the possibility that Leu34 carriers gain more cardioprotection from prophylactic aspirin than Val34 homozygotes.

The picture is not uniformly protective. In patients with atrial fibrillation, the Leu34 allele was independently associated with elevated IL-6 and tissue factor levels⁹⁹ atrial fibrillation, the Leu34 allele was independently associated with elevated IL-6 and tissue factor levels
Marín et al., J Mol Cell Cardiol 2004, suggesting it may modulate the prothrombotic-inflammatory state in this condition. One study in coronary artery disease patients on dual antiplatelet therapy found Leu34 homozygotes had shorter clot formation time on thromboelastography and higher rates of recurrent MI, though this finding requires replication.

Practical Actions

For Leu34 carriers, the main implication is awareness of a moderately favorable fibrinolytic profile. The variant does not eliminate thrombotic risk — it shifts the clot formation-dissolution balance slightly toward easier lysis. This is most relevant in the context of elevated fibrinogen (common with chronic inflammation, smoking, obesity, or metabolic syndrome): where a Val/Val individual's clots would grow denser, Leu34 clots remain more permeable.

Elevated fibrinogen reduces the protective effect of the Leu34 allele. Monitoring fibrinogen levels is clinically meaningful for Leu34 homozygotes because their protection depends on fibrinogen being in the normal range.

Carriers with established cardiovascular disease taking low-dose aspirin may derive disproportionate benefit from aspirin's interaction with the Leu34-enhanced FXIII activation rate — this is a genotype-aspirin interaction, not a reason to start aspirin de novo.

Interactions

The Val34Leu effect on VTE is modified by fibrinogen levels — protective at normal fibrinogen, attenuated at elevated concentrations. Fibrinogen is encoded by three genes (FGA, FGB, FGG), and variants in beta-fibrinogen (rs1800787, rs1800790) influence fibrinogen levels and clot structure independently. The combination of Val34Leu with beta-fibrinogen variants affecting fibrinogen concentration or polymerization may have compounding effects on clot architecture not captured by either variant alone.

Factor V Leiden (rs6025) and prothrombin G20210A (rs1799963) are the major inherited thrombophilia alleles. In carriers of Factor V Leiden, the Leu34 allele may partially offset the procoagulant effect, though the interaction is not large enough to eliminate the clinical significance of Factor V Leiden status.